Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AMPA antagonist
talampanel · 4 trials · 6 indications
Change in frequency of recognizable seizures as measured by entries in a seizure diary
| Arm | Type | Description |
|---|---|---|
| Talampanel 50mg | EXPERIMENTAL | 50mg Talampanel 3 times per day |
| Talampanel 25mg | EXPERIMENTAL | 25mg Talampanel 3 times per day |
| Placebo | PLACEBO_COMPARATOR | placebo 3 times per day |
| enzyme-inducing antiseizure drug | EXPERIMENTAL | A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group. |
| 1 | PLACEBO_COMPARATOR | Enzyme-inducing placebo TID |
| 2 | EXPERIMENTAL | Enzyme-inducing Talampanel 35 mg TID |
| 3 | EXPERIMENTAL | Enzyme-inducing TLP 50mg TID |
| 4 | PLACEBO_COMPARATOR | Non-enzyme-inducing placebo TID |
| 5 | EXPERIMENTAL | Non-enzyme-inducing TLP 25mg TID |
| 6 | EXPERIMENTAL | Non-enzyme-inducing TLP 35mg TID |
| Name | Type | Description |
|---|---|---|
| Talampanel | DRUG | capsules Talampanel, 3 times per day, 52 weeks |
| placebo | OTHER | capsules, placebo, 3 times a day, for 52 weeks |
| Radiation Therapy (RT) 5 days a week + | RADIATION | - |
| temozolomide(TMZ) 75mg | DRUG | temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks |
| adjuvant TMZ 200mg | DRUG | adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months. |
Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. Inclusion Criteria: 1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria. 2. Subject has experienced his/her ...
Top 14 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 3 | PHASE3 | Tofersen, BIIB147 |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | ION363 |
| Corcept Therapeutics Incorporated. | CORT | 1 | PHASE2 | Dazucorilant |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | VHB937 |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-166 |
| Coya Therapeutics, Inc. | COYA | 1 | PHASE2 | COYA 302 |
| Brainstorm-Cell Therapeutics | BCLI | 1 | PHASE3 | NurOwn |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY4256984 |
| Clene Inc | CLNN | 1 | PHASE2 | CNMAu8 |
| Amylyx Pharmaceuticals, Inc. | AMLX | 1 | PHASE1 | AMX0114 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | ALN-SOD |
| Insmed Incorporated | INSM | 1 | PHASE1 | INS1202 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-162 |
| Tiziana Life Sciences Ltd. | TLSA | 1 | PHASE2 | Foralumab |
Talampanel is an investigational small molecule developed by Teva Pharmaceutical Industries Limited (ticker TEVA). It has been studied in Phase 2 clinical trials for neurology indications including amyotrophic lateral sclerosis (ALS), epilepsy, glioblastoma multiforme, and dyskinesias in Parkinson's disease. It is not described as approved and remains an investigational agent.
Talampanel targets GRIA1 and GRIA2, subunits of the AMPA-type glutamate receptor. It acts as an antagonist at these receptors, blocking AMPA receptor mediated glutamate signaling. This target class places talampanel among anti-glutamatergic compounds explored for neurological conditions such as ALS and epilepsy.
Talampanel is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva sponsored the clinical trial program evaluating the compound across neurology indications, including ALS, epilepsy, glioblastoma multiforme, and dyskinesias in Parkinson's disease.
Talampanel is in Phase 2 development. Its clinical program includes Phase 2 trials in ALS, epilepsy, and glioblastoma multiforme, plus a Phase 1 trial in advanced Parkinson's disease and dyskinesias. All listed trials are completed, and no active trials are ongoing.
Talampanel has been studied in completed trials including NCT00696332, a Phase 2 placebo-controlled ALS trial enrolling 559 patients across the United States, Europe, Canada, and Israel; NCT00267592 in glioblastoma multiforme; NCT00034814 in partial seizures; and NCT00036296 in advanced Parkinson's disease and dyskinesias.
Talampanel was studied as a treatment for amyotrophic lateral sclerosis in a Phase 2, randomized, double-blind, placebo-controlled trial, NCT00696332, which enrolled 559 adults aged 18 and older across ten countries. The trial is completed. Talampanel is investigational and is not described as an approved ALS therapy.